Johnson & Johnson
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey.
Not to be confused with S. C. Johnson & Son.
"J&J" and "JNJ" redirect here. For other uses, see J & J (disambiguation) and JNJ (disambiguation).
The company operates 2 divisions: Innovative Medicine (64% of 2025 revenues) and MedTech (36% of 2025 revenues).[1]
Major products produced by the Innovative Medicine division are CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma (2.0% of revenues); DARZALEX (daratumumab and hyaluronidase-fihj), also for multiple myeloma (15.2% of revenues); ERLEADA (apalutamide), for prostate cancer (3.8% of revenues); REMICADE (infliximab), for inflammatory diseases (1.9% of revenues); SIMPONI/SIMPONI ARIA (golimumab), for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis (pJIA) (2.8% of revenues); STELARA (ustekinumab), for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis (6.5% of revenues); TREMFYA (guselkumab), for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis (5.5% of revenues); INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for schizophrenia (4.1% of revenues); SPRAVATO (Esketamine), a nasal spray for depression (1.8% of revenues); OPSUMIT (macitentan)/OPSYNVI (macitentan/tadalafil) for pulmonary arterial hypertension (2.5% of revenues); and UPTRAVI (selexipag) for pulmonary arterial hypertension (2.0% of revenues).[1] The MedTech division produces products used for cardiovascular (9.5% of revenues), orthopaedics (DePuy Synthes) (9.8% of revenues), surgery (Ethicon) (10.8% of revenues), and vision treatments (Johnson & Johnson Vision) (5.8% of revenues).[1]
The company is ranked 48th on the *Fortune* 500[2] and 42nd on the *Forbes* Global 2000.[3]
Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.[4]
Johnson & Johnson was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, selling ready-to-use sterile surgical dressings. It developed some of the most recognizable healthcare products, including the first commercial first aid kit, maternity kits, baby powder, Band-Aids, Tylenol, and contact lens. It developed breakthrough treatments including RhoGAM for Rh incompatibility, HIV therapies, and the antidepressant Spravato (esketamine). The company has played major roles during public health crises including the Spanish flu and the COVID-19 pandemic.
Johnson & Johnson has faced significant lawsuits related to hip implant failures, Risperdal marketing claims, transvaginal mesh, and talc-related cancer cases.
Early corrosive sublimate cotton packaging with the signature logo, c. 1887
Variation of logo used from the company's establishment until September 14, 2023.
Chairmen history
- Robert Wood Johnson I (1887–1910)
- James Wood Johnson (1910–1932)
- Robert Wood Johnson II (1932–1963)
- Philip B. Hofmann (1963–1973)
- Richard B. Sellars (1973–1976)
- James E. Burke (1976–1989)
- Ralph S. Larsen (1989–2002)
- William C. Weldon (2002–2012)
- Alex Gorsky (2012–2022)
- Joaquin Duato (2023–present)[115][116][117]
Johnson & Johnson business segments| Innovative Medicine[125] | MedTech[126] |
Immunology Cardiovascular & metabolic disease Pulmonary hypertension Infectious diseases & vaccines Neuroscience Oncology | Interventional solutions Orthopaedics Surgery (general & advanced) Vision |
Innovative Medicine
Main article: Janssen Pharmaceuticals
The Innovative Medicine (formerly known as pharmaceuticals) segment is focused on six therapeutic areas: immunology (rheumatoid arthritis, inflammatory bowel disease and psoriasis); infectious diseases (HIV/AIDS); neuroscience (mood disorders, neurodegenerative disorders and schizophrenia); oncology (solid tumours including lung cancer, prostate cancer and bladder cancer, and hematologic malignancies); cardiovascular, metabolism, retina (thrombosis and diabetes), and pulmonary hypertension (pulmonary arterial hypertension).[125][1]
MedTech
The Cardiovascular & Specialty Solutions Group includes electrophysiology products that diagnose and treat cardiac arrhythmias; devices used in the endovascular treatment of hemorrhagic and ischemic stroke; solutions that focus on breast reconstruction and aesthetics, and ear, nose and throat procedures.[1]
The DePuy Synthes orthopaedics portfolio is composed of specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS digital surgery portfolio.[1]
The Ethicon surgery portfolio includes advanced surgical innovations and solutions such as sutures, staplers, energy devices, and advanced hemostats along with interventional ablation, surgical robotics, and digital solutions.[1]
The Johnson & Johnson Vision portfolio includes contact lenses, intraocular lens, automated treatment for dry eye, and four brands of laser vision correction systems.[1]
See PDF for complete article downloaded
Wednesday, June 17, 2026 10:29AM
rk NOTE: A researcher with lots of time on their hands could sus out my theory that this company, along with their partners, are experimenting on humans (the general population) and building robots (like BIDEN the A.i. Pen!).